查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1986883

反義和RNAi療法市場規模、佔有率、趨勢和預測：按技術、給藥途徑、應用和地區分類，2026-2034年

Antisense & RNAi Therapeutics Market Size, Share, Trends and Forecast by Technology, Route of Administration, Application, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

2025年全球反義和RNAi療法市場規模為19.1億美元。展望未來，IMARC Group預測該市場將在2026年至2034年間以6.74%的複合年成長率成長，到2034年達到34.3億美元。目前，北美市場主導地位，預計2025年將佔40%的市場。該地區擁有許多優勢，例如先進的生物技術基礎設施、大量的公共和私人研究投資、有利於快速核准治療方法的法規環境，以及較高的遺傳疾病患病率，所有這些因素都促進了反義和RNAi療法市場佔有率的成長。

受多種強勁因素的推動，全球反義寡核苷酸和RNAi療法市場正經歷著蓬勃發展。遺傳性疾病、代謝性疾病和慢性疾病在全球範圍內的發病率不斷上升，使得針對基因靜默療法的需求空前高漲，這些療法旨在解決疾病的根本分子機制，而不僅僅是緩解症狀。寡核苷酸化學的進步，特別是硫代磷酸酯骨架的引入和化學修飾，顯著提高了藥物的穩定性、特異性和生物利用度。對RNA生物學更深入的科學理解，拓展了以往難以治療疾病的治療選擇。全球對生物製藥研發的投資正在加速新型治療標靶的發現。越來越多的臨床試驗正在研究反義寡核苷酸和RNAi平台在多種適應症中的應用，從而擴大了其應用範圍。基因組分析技術推動的個人化醫療轉型，也為患者量身定做治療方案創造了機遇，這預示著反義寡核苷酸和RNAi治療方法市場在這個專業化且快速發展的領域擁有光明的前景。

由於多種因素，美國正崛起為反義和RNAi療法市場的領先地區。美國擁有世界一流的生物技術公司、學術研究機構和政府資助計畫組成的緊密網路，這些機構攜手合作，共同推動基於RNA的療法的發現。美國食品藥物管理局（FDA）管理的健全法規結構，透過快速通道、突破性療法認定和加速核准等加速途徑，積極支持創新，從而加速寡核苷酸候選化合物的臨床應用。患者的高度認知和參與臨床試驗的意願，也為罕見遺傳疾病、神經退化性疾病和腫瘤適應症的研發提供了支持。 2025年，RNAi療法領域的領導企業Alnylam Pharmaceuticals, Inc.宣布計劃擴建其位於麻薩諸塞州諾頓的先進製造廠。該公司計劃投資2.5億美元，建造業內首個專門用於siRNA酶連接生產的專用設施。這項投資有望大幅提高產能並大幅降低製造成本，使 Alnilam 能夠支持其不斷擴大的新型療法產品線中未來的產品上市。

反義和RNAi療法的市場趨勢：

藥物輸送系統的技術進步

藥物遞送技術的快速發展是此治療領域的關鍵驅動力。脂質體奈米顆粒正逐漸成為將短干擾RNA（siRNA）和反義寡核苷酸遞送至目標細胞的黃金標準，可提高細胞內攝取並減少核酸酶分解。 GalNAc-siRNA偶聯平台徹底革新了肝臟標靶化，與傳統製劑相比，能夠以顯著較低的劑量將藥物精準遞送至肝細胞。這些創新提高了RNA類藥物的治療指數，並實現了皮下給藥方案，從而增強了患者的依從性。諸如硫代磷酸酯結合、2'-O-甲基化和鎖核酸（LNA）基序等先進的化學修飾進一步延長了寡核苷酸療法的半衰期並提高了其效力。 2025年的研究重點將日益集中於拓展遞送系統，使其能夠到達肝臟以外的肌肉組織、中樞神經系統和肺細胞。人工智慧正被整合到寡核苷酸序列的設計中，以提高標靶選擇性並最大限度地減少脫靶效應。

遺傳性疾病和慢性病盛行率增加

全球遺傳性疾病、罕見疾病和慢性病負擔日益加重，顯著推動了反義寡核苷酸和RNA干擾療法市場的成長。亨廷頓舞蹈症、遺傳性轉甲狀腺素類澱粉沉積症樣變性、脊髓性肌肉萎縮症以及多種遺傳性癌症等疾病缺乏有效的傳統藥物治療方法方法，因此對基於核酸的基因靜默療法的需求持續旺盛。反義寡核苷酸和RNA干擾平台透過在mRNA層級選擇性地定序致病基因，為治療提供了獨特的優勢，從而能夠針對異常蛋白質表現引起的疾病進行標靶干預。全球人口老化加劇，導致與老齡化相關的遺傳性和退化性疾病的盛行率上升，擴大了符合這些治療方法適用人群的範圍。根據美國國立衛生研究院（NIH）統計，目前已發現7,000多種罕見疾病，其中約80%為遺傳性疾病，影響全球約3億人口。這種巨大的未滿足需求持續推動著強大的研發投資和強勁的研發管線擴張，反映了全球多個治療適應症的反義和 RNAi 療法市場的趨勢。

新治療方法的有利監管條件

全球範圍內有利的法規環境是推動反義寡核苷酸和RNA干擾療法市場成長的關鍵因素。包括美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）在內的監管機構正在實施專門機制，以加速新型核酸療法的研發和核准。孤兒藥認定、突破性治療方法認定、快速核准和優先審評券等舉措，為企業投資反義寡核苷酸和RNA干擾療法的研發提供了切實有效的獎勵，尤其是在罕見疾病和醫療需求尚未得到充分滿足的疾病領域。這些認定縮短了研發時間和相關成本，使中小型生物技術公司能夠與大型製藥企業公平競爭。加速核准流程正在加快該領域的核准速度，並增強商業性對這些治療方法的信心。 2025年3月，美國FDA核准了Qfitlia（fitusiran），這是一種用於治療A型和B型血友病的皮下siRNA療法。這是Alnilam公司研發的第六種獲美國市場核准的RNAi藥物，顯示法規核准流程正在加速推進。這項突破性進展進一步增強了投資者對反義和RNAi療法領域長期潛力的信心。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第3章執行摘要

第4章：引言

第5章：全球反義與RNAi治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依技術分類

  • RNA干擾
    • 主要部分
      • siRNA
      • miRNA
  • 反義RNA

第7章 市場區隔：依給藥途徑

  • 靜脈注射
  • 皮下注射
  • 鞘內給藥
  • 肺部給藥
  • 腹腔注射
  • 其他

第8章 市場區隔：依應用領域分類

  • 腫瘤學
  • 心血管疾病（CVD）
  • 呼吸系統疾病
  • 腎臟疾病
  • 神經退化性疾病
  • 遺傳性疾病
  • 感染疾病
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Alnylam Pharmaceuticals Inc.
    • Arbutus Biopharma Corporation
    • Arrowhead Pharmaceuticals Inc.
    • Benitec Biopharma Ltd.
    • Bio-Path Holdings Inc.
    • Dicerna Pharmaceuticals Inc.（Novo Nordisk A/S）
    • Ionis Pharmaceuticals Inc.
    • OliX Pharmaceuticals Inc.
    • Phio Pharmaceuticals Corp.
    • Sarepta Therapeutics Inc.
    • Silence Therapeutics
    • Sirnaomics Inc.
Product Code: SR112026A6549

The global antisense & RNAi therapeuticmarket size was valued at USD 1.91 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 3.43 Billion by 2034, exhibiting a CAGR of 6.74% from 2026-2034. North America currently dominates the market, holding a market share of 40% in 2025. The region benefits from advanced biotechnology infrastructure, significant public and private research investment, a favorable regulatory environment enabling expedited therapy approvals, and high prevalence of genetic disorders among the population, all contributing to the antisense & RNAi therapeutics market share.

The global antisense & RNAi therapeutics market is experiencing robust expansion driven by several compelling factors. The rising global incidence of genetic, metabolic, and chronic diseases is generating unprecedented demand for targeted gene-silencing therapies that address molecular root causes rather than symptoms. Advancements in oligonucleotide chemistry, particularly the introduction of phosphorothioate backbones and chemical modifications, have significantly enhanced drug stability, specificity, and bioavailability. Growing scientific understanding of RNA biology is expanding the therapeutic landscape to previously untreatable conditions. Global investments in biopharmaceutical research and development are accelerating the identification of novel therapeutic targets. The ongoing proliferation of clinical trials investigating antisense oligonucleotide and RNAi platforms across multiple indications is broadening their applicability. The shift toward personalized medicine, driven by genomic profiling technologies, is also creating tailored treatment opportunities, reflecting positive antisense & RNAi therapeutics market outlook for this specialized and rapidly advancing modality.

The United States has emerged as a major region in the antisense & RNAi therapeutics market owing to many factors. The country hosts a dense network of world-class biotechnology companies, academic research institutions, and government-funded programs that collectively advance RNA-based therapeutic discovery. A robust regulatory framework administered by the FDA actively supports innovation through expedited pathways including Fast Track, Breakthrough Therapy Designation, and Accelerated Approval, enabling quicker clinical translation of oligonucleotide candidates. High patient awareness and participation in clinical trials supports pipeline development across rare genetic, neurodegenerative, and oncological indications. In 2025, Alnylam Pharmaceuticals, Inc., a top company in RNAi therapeutics, revealed its intention to expand its advanced manufacturing plant located in Norton, Massachusetts. The Company is set to invest $250 million to develop what is expected to be the industry's first fully dedicated, proprietary facility for siRNA enzymatic-ligation manufacturing. This investment is anticipated to greatly increase capacity, considerably lower production costs, and enable Alnylam to assist future launches within its expanding pipeline of possible new treatments

ANTISENSE & RNAI THERAPEUTICS MARKET TRENDS:

Technological Advancements in Drug Delivery Systems

The rapid evolution of drug delivery technologies is a key factor propelling this therapeutic field. Lipid nanoparticles have emerged as the gold standard for delivering short interfering RNA and antisense oligonucleotides into target cells, improving cellular uptake and reducing nuclease-mediated degradation. GalNAc-siRNA conjugate platforms have revolutionized hepatic targeting, enabling precise delivery to liver cells at substantially lower doses compared to earlier formulations. These innovations have improved the therapeutic index of RNA-based medicines, enabling subcutaneous administration regimens that enhance patient compliance. Advanced chemical modifications including phosphorothioate linkages, 2'-O-methyl groups, and locked nucleic acid motifs have further extended the half-life and potency of oligonucleotide therapeutics. Research efforts in 2025 are increasingly focused on expanding delivery systems beyond the liver to reach muscle tissue, the central nervous system, and lung cells. Artificial intelligence is being integrated into oligonucleotide sequence design to improve target selectivity and minimize off-target effects.

Rising Prevalence of Genetic and Chronic Diseases

The escalating global burden of genetic, rare, and chronic diseases is significantly supporting the antisense & RNAi therapeutics market growth. Conditions such as Huntington's disease, hereditary transthyretin amyloidosis, spinal muscular atrophy, and various hereditary cancers lack effective treatments using conventional pharmaceutical approaches, creating sustained demand for nucleic acid-based gene-silencing therapies. Antisense oligonucleotides and RNAi platforms offer a unique therapeutic advantage by selectively silencing disease-causing genes at the mRNA level, providing targeted intervention for conditions driven by aberrant protein expression. The growing aging global population is amplifying the prevalence of age-related genetic and degenerative disorders, expanding the addressable patient base for these therapeutics. According to the National Institutes of Health (NIH), over 7,000 rare diseases have been identified, with approximately 80% having a genetic origin, collectively affecting an estimated 300 million people worldwide. This enormous unmet medical need continues to generate strong research investments and robust pipeline expansion, reflecting growing antisense & RNAi therapeutics market trends across multiple therapeutic indications globally.

Favorable Regulatory Landscape for Novel Therapies

The supportive global regulatory environment represents a significant enabler of the antisense & RNAi therapeutics market forecast. Regulatory agencies including the FDA in the United States and the European Medicines Agency have implemented specialized mechanisms to accelerate the development and approval of novel nucleic acid therapeutics. Programs such as Orphan Drug Designation, Breakthrough Therapy Designation, Fast Track approval, and Priority Review vouchers provide meaningful incentives for companies to invest in antisense and RNAi development, particularly for rare and underserved disease areas. These designations reduce development timelines and associated costs, enabling smaller biotechnology firms to compete effectively alongside large pharmaceutical organizations. Accelerated pathways have facilitated a steady stream of approvals in this class, reinforcing commercial confidence in these modalities. In March 2025, the U.S. FDA approved Qfitlia (fitusiran), a subcutaneous siRNA therapeutic for hemophilia A or B, marking the sixth Alnylam-discovered RNAi medicine to receive U.S. market clearance and demonstrating the accelerating pace of regulatory advancement. This milestone reinforces investor confidence in the Antisense & RNAi Therapeutics sector's long-term potential.

ANTISENSE & RNAI THERAPEUTICS INDUSTRY SEGMENTATION:

Analysis by Technology:

  • RNA Interference
    • siRNA
    • miRNA
  • Antisense RNA

RNA Interference holds 60% of the market share. RNA interference operates through small interfering RNA (siRNA) and microRNA (miRNA) molecules that engage the RNA-induced silencing complex (RISC) to achieve targeted gene silencing at the post-transcriptional level. This mechanism provides unparalleled precision in suppressing disease-causing gene expression, making it particularly effective for conditions where a specific pathogenic protein must be inhibited. The siRNA pathway has been the basis for several FDA-approved medicines, demonstrating proven clinical efficacy across hepatic, hematological, and neurological indications. Key advantages of RNAi over antisense approaches include greater potency at lower doses and catalytic activity within the RISC complex, enabling repeated cycles of gene silencing. Ongoing research into extra-hepatic delivery is expected to unlock new application areas including neurology, oncology, and muscle diseases, further solidifying the dominant position of RNA interference within this expanding market.

Analysis by Route of Administration:

  • Intravenous Route
  • Subcutaneous Route
  • Intrathecal Route
  • Pulmonary Delivery
  • Intraperitoneal Injection
  • Others

Intravenous Route leads the market with a share of 26%. The intravenous route enables systemic delivery of antisense oligonucleotides and RNAi therapeutics, facilitating rapid distribution throughout the bloodstream for conditions requiring broad biodistribution. Intravenous administration is particularly relevant for oncological and hematological applications where systemic circulation is essential for reaching tumor cells and blood-borne targets. Lipid nanoparticle-encapsulated RNAi therapeutics such as patisiran, the first FDA-approved siRNA drug, were initially formulated for intravenous delivery, establishing a strong clinical precedent for this administration route. The well-established hospital infusion infrastructure globally supports broad adoption of intravenous RNA therapeutics in developed healthcare markets. This route remains essential for the clinical management of conditions requiring rapid therapeutic effect or systemic distribution. Although newer formulations are transitioning toward subcutaneous delivery for improved patient convenience, the intravenous route retains a significant and well-validated position across multiple RNA therapeutic indications globally.

Analysis by Application:

  • Oncology
  • Cardiovascular Diseases (CVDs)
  • Respiratory Disorders
  • Renal Diseases
  • Neurodegenerative Disorders
  • Genetic Disorders
  • Infectious Diseases
  • Others

Oncology dominates the market, with a share of 31%. The application of antisense oligonucleotides and RNAi therapeutics in oncology represents one of the most dynamic and rapidly growing segments in this field. Cancer, by its nature, is driven by aberrant gene expression, making it an ideal candidate for nucleic acid-based gene-silencing approaches. RNAi and antisense technologies enable selective suppression of oncogenes, resistance pathways, and immune evasion mechanisms that drive tumor growth and survival. Multiple RNAi-based oncology programs are currently advancing through clinical development pipelines, targeting genes such as VEGF, kinesin spindle protein, and various tumor-specific mRNAs. The growing understanding of cancer genomics, driven by next-generation sequencing, is identifying novel targetable sequences for antisense and RNAi drug design. This persistent unmet need across solid and hematological cancers continues to propel the Antisense & RNAi Therapeutics sector's oncology-focused applications.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America, accounting for 40% of the share, enjoys the leading position in the market. The region's dominance is underpinned by exceptional biotechnology infrastructure, world-class academic research institutions, substantial public and private sector R&D investment, and a regulatory environment that actively facilitates the development and commercialization of novel nucleic acid therapeutics. The United States in particular is home to pioneering companies that led the development of the world's first approved antisense and RNAi medicines. High patient awareness, widespread reimbursement coverage, and strong healthcare spending collectively drive demand for advanced therapies across genetic, neurological, and cardiovascular indications. In 2025, variouspharmaceutical and biotechnology companies were actively working on antisense oligonucleotide programs in the United States, as reported by clinical pipeline analyses, highlighting the region's exceptional research density. Canada also contributes to regional growth through government-funded biotechnology initiatives and a growing base of RNA therapeutics startups, further reinforcing North America's leading regional position within the global landscape.

KEY REGIONAL TAKEAWAYS:

UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET ANALYSIS

The United States is the world's largest individual market for antisense & RNAi therapeutics, driven by a unique combination of scientific leadership, regulatory innovation, and healthcare infrastructure. The country's biotechnology ecosystem, centered in regions such as Greater Boston, the San Francisco Bay Area, and Research Triangle Park, houses the largest concentration of RNA therapeutics companies globally. The National Institutes of Health (NIH) continues to direct substantial funding toward foundational RNA biology and clinical translation research, supporting a robust pipeline of investigational oligonucleotide therapies. Favorable reimbursement policies for approved specialty therapeutics, including orphan drugs, enable broad commercial uptake of high-cost RNA medicines across patient populations. The FDA's commitment to novel therapy pathways, evidenced by multiple Breakthrough Therapy and Fast Track designations for antisense and RNAi candidates, significantly accelerates development timelines. In April 2025, the FDA granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide targeting tau protein, for Alzheimer's disease treatment, reflecting the agency's supportive stance toward advanced nucleic acid medicines. The country's large patient population with rare genetic disorders, neurological diseases, and oncological conditions continues to generate consistent demand for innovative gene-silencing therapies throughout the forecast period.

EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET ANALYSIS

Europe represents the second-largest region in the antisense & RNAi therapeutics market, supported by a mature pharmaceutical industry, strong academic research base, and harmonized regulatory frameworks coordinated by the European Medicines Agency. European countries including Germany, France, the United Kingdom, and Switzerland are home to internationally recognized biotechnology centers and academic institutions that actively contribute to RNA therapeutics innovation. The EMA has implemented favorable regulatory designations, including orphan medicine status and adaptive licensing pathways, to incentivize development of treatments for rare genetic diseases where antisense and RNAi approaches show strong promise. Reimbursement systems across major European markets support patient access to newly approved specialty therapies. High incidence of hereditary transthyretin amyloidosis, Duchenne muscular dystrophy, and rare genetic disorders in European patient populations continues to drive steady clinical demand.

ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET ANALYSIS

Asia-Pacific is the fastest-growing region in the antisense & RNAi therapeutics market, driven by rapidly expanding healthcare infrastructure, increasing biotechnology investment, and growing patient awareness of advanced gene-silencing therapies. Countries such as China, Japan, South Korea, and India are intensifying domestic research and development capabilities in nucleic acid therapeutics, with several local biotechnology companies pursuing RNAi-based programs. Government initiatives across the region are supporting the development of RNA-based precision medicines as part of broader national biotechnology strategies. According to the World Health Organization (WHO), Asia-Pacific was home to over 4.7 billion people as of 2024, representing one of the world's largest patient pools for rare, genetic, and chronic diseases requiring advanced therapeutic interventions. The expansion of clinical trial activity and growing regulatory harmonization with international standards are positioning Asia-Pacific as a key growth engine for the global Antisense & RNAi Therapeutics sector.

LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET ANALYSIS

Latin America represents an emerging growth opportunity in the antisense & RNAi therapeutics market, underpinned by a growing patient population, rising healthcare expenditure, and increasing government focus on advanced biopharmaceutical access. Brazil and Mexico lead regional activity, with expanding clinical trial participation and evolving regulatory frameworks being developed to accommodate novel genetic medicines. Growing awareness of rare disease management, supported by patient advocacy organizations and international pharmaceutical partnerships, is enhancing access to approved RNA therapeutics. Moreover, the heightened occurrence of new cancer diagnoses in 2024 is highlighting the significant unmet need for targeted oncology therapeutics including gene-silencing modalities and underscoring the region's long-term market potential.

MIDDLE EAST AND AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET ANALYSIS

The Middle East and Africa market for antisense & RNAi therapeutics is at an early development stage but exhibits meaningful long-term potential. Gulf Cooperation Council countries, particularly Saudi Arabia and the United Arab Emirates, are investing substantially in healthcare infrastructure modernization and advanced pharmaceutical access as part of national economic diversification strategies. Growing awareness of genetic diseases and rare conditions, combined with rising healthcare expenditure, is creating demand for specialized therapies. According to the World Health Organization (WHO), the Middle East and Africa region recorded a major number of new cancer cases in 2024, highlighting growing unmet therapeutic need and creating incremental opportunities for the adoption of innovative antisense and RNAi therapies across the region.

COMPETITIVE LANDSCAPE:

The antisense & RNAi therapeutics market is characterized by a dynamic competitive environment comprising established pharmaceutical leaders, dedicated RNA therapeutics companies, and innovative biotechnology entrants. Leading players maintain competitive positions through proprietary delivery platform technologies, extensive patent portfolios covering oligonucleotide chemistry and target sequences, and robust clinical pipelines spanning multiple disease indications. Strategic alliances between large pharmaceutical companies and specialized RNA biotechnology firms have become a defining feature of the competitive landscape, enabling shared expertise in drug development and commercialization. Companies are increasingly leveraging conjugate delivery technologies, particularly GalNAc-siRNA systems, to differentiate their product candidates through improved potency, selectivity, and dosing convenience. Manufacturing scale-up has emerged as a key competitive dimension, with major players investing in proprietary production platforms to reduce costs and support pipeline expansion. Ongoing competition for orphan drug designations and breakthrough therapy status provides an additional avenue for differentiation in this specialized and rapidly evolving market.

The report provides a comprehensive analysis of the competitive landscape in the antisense & RNAi therapeutics market with detailed profiles of all major companies, including:

  • Alnylam Pharmaceuticals Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals Inc.
  • Benitec Biopharma Ltd.
  • Bio-Path Holdings Inc.
  • Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
  • Ionis Pharmaceuticals Inc.
  • OliX Pharmaceuticals Inc.
  • Phio Pharmaceuticals Corp.
  • Sarepta Therapeutics Inc.
  • Silence Therapeutics
  • Sirnaomics Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the antisense & RNAi therapeutics market?

2. What is the future outlook of the antisense & RNAi therapeutics market?

3. What are the key factors driving the antisense & RNAi therapeutics market?

4. Which region accounts for the largest antisense & RNAi therapeutics market share?

5. Which are the leading companies in the global antisense & RNAi therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antisense & RNAi Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 RNA Interference
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 siRNA
      • 6.1.2.2 miRNA
    • 6.1.3 Market Forecast
  • 6.2 Antisense RNA
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Intravenous Route
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Subcutaneous Route
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Intrathecal Route
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pulmonary Delivery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Intraperitoneal Injection
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Cardiovascular Diseases (CVDs)
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Respiratory Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Renal Diseases
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Neurodegenerative Disorders
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Genetic Disorders
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Infectious Diseases
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast
  • 8.8 Others
    • 8.8.1 Market Trends
    • 8.8.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Alnylam Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Arbutus Biopharma Corporation
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Arrowhead Pharmaceuticals Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Benitec Biopharma Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Bio-Path Holdings Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Ionis Pharmaceuticals Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 OliX Pharmaceuticals Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Phio Pharmaceuticals Corp.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Sarepta Therapeutics Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Silence Therapeutics
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
    • 14.3.12 Sirnaomics Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio

List of Figures

  • Figure 1: Global: Antisense & RNAi Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Antisense & RNAi Therapeutics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Antisense & RNAi Therapeutics Market: Breakup by Technology (in %), 2025
  • Figure 5: Global: Antisense & RNAi Therapeutics Market: Breakup by Route of Administration (in %), 2025
  • Figure 6: Global: Antisense & RNAi Therapeutics Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Antisense & RNAi Therapeutics Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Antisense & RNAi Therapeutics (RNA Interference) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Antisense & RNAi Therapeutics (RNA Interference) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Antisense & RNAi Therapeutics (Oncology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Antisense & RNAi Therapeutics (Oncology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Antisense & RNAi Therapeutics (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Antisense & RNAi Therapeutics (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: North America: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: North America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: United States: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: United States: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Canada: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Canada: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Asia-Pacific: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Asia-Pacific: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: China: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: China: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Japan: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Japan: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: India: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: India: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: South Korea: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: South Korea: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Australia: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Australia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Indonesia: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Indonesia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Europe: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Europe: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Germany: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Germany: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: France: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: France: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: United Kingdom: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: United Kingdom: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Italy: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Italy: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Spain: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Spain: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Russia: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Russia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Latin America: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Latin America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Brazil: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Brazil: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Mexico: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Mexico: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Middle East and Africa: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Middle East and Africa: Antisense & RNAi Therapeutics Market: Breakup by Country (in %), 2025
  • Figure 88: Middle East and Africa: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 89: Global: Antisense & RNAi Therapeutics Industry: SWOT Analysis
  • Figure 90: Global: Antisense & RNAi Therapeutics Industry: Value Chain Analysis
  • Figure 91: Global: Antisense & RNAi Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antisense & RNAi Therapeutics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 3: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 4: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Antisense & RNAi Therapeutics Market: Competitive Structure
  • Table 7: Global: Antisense & RNAi Therapeutics Market: Key Players